Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
ACADEMIA
Camostat Potential Treatment for COVID-19: German Study
The serine protease inhibitor camostat mesylate could have the potential to be used as a treatment for COVID-19, according to results from an in vitro study conducted by a German research group using a human cell line to identify the…
To read the full story
Related Article
- Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
- Ono Curbing Camostat Supplies after Drug Reported as Potential COVID-19 Hopeful
April 15, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Pancreatitis Drug Nafamostat Potentially Effective for COVID-19: Researchers
March 19, 2020
ACADEMIA
- Keep Public Funding for COVID Drugs to Get through This Winter: Academic Societies
May 25, 2023
- Osaka University Completes Transplants of iPS Cell-Derived Cardiac Cell Sheet
May 22, 2023
- OB/GYN Society Aims for Early Use of Oral Abortion Pill at Clinics without Beds
May 12, 2023
- Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
- More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
President Joe Biden enacted the Inflation Reduction Act (IRA) on August 16, 2022, significantly affecting Medicare prescription drug coverage and introducing targeted changes to Medicaid, the Children’s Health Insurance Program, and private health insurance. In January 2023, the Centers for…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…